ER positive

P=N/A, N=1050, Recruiting, Institut Claudius Regaud | Not yet recruiting --> Recruiting

P1/2, N=99, Recruiting, Forward Pharmaceuticals Co., Ltd. | Phase classification: P1 --> P1/2 | Trial completion date: Feb 2026 --> Mar 2028 | Trial primary completion date: Nov 2025 --> Mar 2026

Importantly, inhibition of lipid accumulation with the fatty acid synthase inhibitor C75 reduced PRG4+ macrophage numbers, attenuated fibrosis, and suppressed lung metastasis. Together, these findings implicate long-term tamoxifen treatment as a potential risk factor for lung metastasis in ER-positive BC by disrupting the lung microenvironment, and suggest that targeting lipid metabolism may represent a therapeutic strategy to limit metastatic progression, particularly in the lung.

P=N/A, N=18, Recruiting, University of Kansas Medical Center | Not yet recruiting --> Recruiting

P=N/A, N=50, Recruiting, Stanford University | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

P=N/A, N=61, Not yet recruiting, St. Antonius Hospital

These images and pathological findings suggest that multiple small axillary masses with haloes on ultrasound are not lymph node metastases of breast cancer. Breast specialists, therefore, should develop therapeutic strategies based on the idea that multiple small axillary nodules with haloes on ultrasound have a high probability of in-breast recurrence.

KDM5B upregulation was significantly negatively correlated with the survival rates in various cancer types, including thyroid, lung, esophageal and colorectal cancers. Overall, these findings establish a novel regulatory axis in cholesterol metabolism, uncover potential therapeutic vulnerabilities in ER+ breast cancer, and suggest that targeting the KDM5B could provide a strategy to curb tumor progression.

Our results suggest that the surface chemistry of silver nanoparticles may facilitate their ability to modulate estrogen signaling and interact with the estrogen receptor. Furthermore, the nanoplastics pollution may influence the cytotoxicity of silver nanoparticles. This paper highlights the importance of endocrine research in breast cancer, particularly within the context of nanoplastics pollution and the use of nanotechnology in breast cancer treatment.

We also discussed implementation challenges, including test standardization, reporting, equity of access, and areas of ongoing uncertainty. This position paper aims to support consistent, equitable, and biologically informed management of endometrial carcinoma in contemporary practice.

P2, N=126, Not yet recruiting, Cancer Care Hospital & Research Centre Foundation, Lahore

P3, N=1978, Not yet recruiting, National Cancer Institute (NCI)